Literature DB >> 9710248

A dimeric bispecific miniantibody combines two specificities with avidity.

K M Müller1, K M Arndt, A Plückthun.   

Abstract

Bispecific antibodies extend the capabilities of nature and might be applied in immunotherapy and biotechnology. By fusing the gene of a single-chain Fv (scFv) fragment to a helical dimerization domain, followed by a second scFv fragment of different specificity, we were able to express a functional protein in E. coli, which is bispecific and has two valencies for each specificity. The dimeric bispecific (DiBi) miniantibody preserves the natural avidity of antibodies in a very small-sized molecule of only 120 kDa. The generality of the principle was shown with a scFv fragment binding the EGF-receptor (named scFv 425) in three combinations with scFv fragments either directed against CD2 (ACID2.M1), phosphorylcholine (McPC603) or fluorescein (FITC-E2). Binding was analyzed by sandwich surface plasmon resonance biosensor (BIAcore) measurements.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710248     DOI: 10.1016/s0014-5793(98)00829-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.

Authors:  Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; William J McBride; Robert M Sharkey; Chien-Hsing Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

Review 2.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

3.  Anti-EGFR-miniantibody-barnase immunoconjugate is highly toxic for human tumor cells.

Authors:  E F Edelweiss; T G Balandin; O A Stremovskiy; S M Deyev; R V Petrov
Journal:  Dokl Biochem Biophys       Date:  2010-10-20       Impact factor: 0.788

4.  Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.

Authors:  T Würdinger; M H Verheije; K Broen; B J Bosch; B J Haijema; C A M de Haan; V W van Beusechem; W R Gerritsen; P J M Rottier
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  The kinetics of antibody binding to Plasmodium falciparum VAR2CSA PfEMP1 antigen and modelling of PfEMP1 antigen packing on the membrane knobs.

Authors:  Lars M Joergensen; Ali Salanti; Tina Dobrilovic; Lea Barfod; Tue Hassenkam; Thor G Theander; Lars Hviid; David E Arnot
Journal:  Malar J       Date:  2010-04-19       Impact factor: 2.979

6.  Insights into the molecular basis of a bispecific antibody's target selectivity.

Authors:  Yariv Mazor; Anna Hansen; Chunning Yang; Partha S Chowdhury; Jihong Wang; Geoffrey Stephens; Herren Wu; William F Dall'Acqua
Journal:  MAbs       Date:  2015       Impact factor: 5.857

7.  GPVI (Glycoprotein VI) Interaction With Fibrinogen Is Mediated by Avidity and the Fibrinogen αC-Region.

Authors:  Rui-Gang Xu; Julia S Gauer; Stephen R Baker; Alexandre Slater; Eleyna M Martin; Helen R McPherson; Cédric Duval; Iain W Manfield; Arkadiusz M Bonna; Steve P Watson; Robert A S Ariëns
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-01-21       Impact factor: 8.311

8.  Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.

Authors:  Edwin Bremer; Marco de Bruyn; Douwe F Samplonius; Theo Bijma; Bram ten Cate; Lou F M H de Leij; Wijnand Helfrich
Journal:  J Mol Med (Berl)       Date:  2008-05-27       Impact factor: 4.599

Review 9.  Design and applications of bispecific heterodimers: molecular imaging and beyond.

Authors:  Haiming Luo; Hao Hong; Sarah P Yang; Weibo Cai
Journal:  Mol Pharm       Date:  2014-04-28       Impact factor: 4.939

10.  A bifunctional converter: fluorescein quenching scFv/fluorogen activating protein for photostability and improved signal to noise in fluorescence experiments.

Authors:  Matthew J Saunders; Ethan Block; Alexander Sorkin; Alan S Waggoner; Marcel P Bruchez
Journal:  Bioconjug Chem       Date:  2014-08-06       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.